Plasmid containing a sequence encoding mRNA with a segmented poly(A) tail
By designing DNA plasmids with specific structures, including nucleotide sequences encoding modified poly(A) tails, the problem of instability of poly(A) tails is solved, and stable amplification and high efficiency in bacterial cells are achieved. mRNA production.
Patent Information
- Application Number
- CN201980066650.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-11
- Filing Date
- 2019-10-10
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-10-10
AI Technical Summary
The prior art is difficult to generate mRNA molecules with a determined poly(A) tail length on a large scale, and the sequence encoding poly(A) tail during amplification in bacterial cells is prone to recombination, resulting in length instability.
Design a DNA plasmid comprising a first nucleotide sequence encoding an mRNA molecule and a second nucleotide sequence encoding a modified poly(A) tail located downstream thereto, characterized by at least two A elements and at least A S element, the total number of A elements is one more than the S element, and any two A elements are separated by one S element.
Recombination of poly(A) tail sequences is significantly reduced in bacterial cells, and the stability and translation efficiency of mRNA molecules in in vitro transcription are improved.
Smart Images

Figure BDA0003012813690000111 
Figure BDA0003012813690000121 
Figure BDA0003012813690000131
Abstract
Description
[0001] The present invention relates to a DNA plasmid, comprising a DNA sequence, which comprises a first nucleotide sequence encoding an mRNA molecule and a second nucleotide sequence encoding a modified poly (A) tail located downstream thereof, wherein the second nucleotide sequence is characterized in that it consists of: at least two A elements, each A element being defined as a nucleotide sequence consisting of 55 to 65 T nucleotides; and at least one S element, each S element consisting of: i) one nucleotide that is not a T nucleotide, or ii) 2 to 10 nucleotides, preferably 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide, wherein the total number of A elements is one more than the total number of S elements, and wherein any two A elements are separated by one S element.
[0002] Genetic information is stored in cells in the form of deoxyribonucleic acid (DNA) and can be transcribed into ribonucleic acid (RNA) when needed. Both DNA and RNA molecules are composed of nucleotides consisting of nitrogenous bases, pentose, and at least one phosphate group. There are different types of RNA molecules, including mRNA molecules that carry genetic information for protein synthesis. In eukaryotes, these mRNA molecules are transcribed from DNA into pre-mature mRNA molecules, which are then modified by adding, for example, 3' polyadenosine (poly (A)) tails. The poly (A) tail is a feature of mature functional mRNA molecules, one of the few known exceptions being histone mRNA (Marzluff et al., 2008, Nat. Rev. Genet., 9 (11): 843-854; Yang et al., 2011, Genome Biology, 12: R16). Then, the mature mRNA molecule is transferred from the nucleus to the cytoplasm, where it is translated into protein. Therefore, the DNA sequence of the mature mRNA molecule, as well as the amount, stability, and translation efficiency, mainly determine the synthesis of the corresponding protein in the cell.
[0003] In order to optimize the synthesis of desired proteins in cells, for example in therapeutic settings, mRNA-based methods represent a promising tool. The advantage of using mRNA molecules is that the molecules have to be introduced only into the cytoplasm of the cell for protein translation (Tavernier et al., 2011, J Control Release, 150(3):238-247; Yamamoto et al., 2009, Eur J Pharm Biopharm, 71(3):484-489). Compared with the corresponding DNA sequence contained in the appropriate vector (such as plasmid), the use of mRNA molecules is easier and more effective, and avoids the considerable risk of changing chromosomal DNA when the plasmid or part of the plasmid is incorporated into the genome. The use of, for example, chemically modified nucleotides has successfully addressed initial challenges associated with introducing mRNA molecules into cells, such as instability of mRNA molecules and immune responses (WO 2011 / 012316; EP patent application number 18 15 6466.7; Karikó et al., 2008, Mol. Ther., 16(11):1833-40). To date, several determinants of mRNA efficiency have been identified and studied, including the efficiency of 5' capping and the composition of the 5' cap, the nature of the untranslated region, codon optimization of the protein-encoding sequence, the presence of miRNA target sequences in the protein-encoding sequence and the untranslated region, and the length of the 3' poly (A) tail (e.g. Thess, et al., 2015, Mol. Ther., 23(9), 1456-1464; Trepotec et al., 2018, Tissue Engineering. Part A, ten. TEA. 2017.0485; Ziemniak et al., 2013, Future Med. Chem., 5(10), 1141-1172).
[0004] In order to improve the efficiency of mRNA-based methods, it is essential to optimize the length of the poly (A) tail. The length of the poly (A) tail is considered to be the main determinant of mRNA turnover, because the degradation of the poly (A) tail is the first step of mRNA degradation before 5' cap hydrolysis or further 3' to 5' degradation (for example, in Lodish et al., Mol. Cell Biol. 4th edition, New York: WH Freeman, 2000, 11.2 part; Ramanathan et al., 2016, Nucleic Acids Res., 44 (16): 7511-7526 reviewed). For example, in mammals, it is reported that the average length of the poly (A) tail is about 200 to 300 nucleotides. In addition, it is reported that the poly (A) tail can show terminal nucleotides other than A nucleotides, such as terminal G nucleotides can block the degradation of the poly (A) tail (Chang et al., 2014, Mol. Cell 53 (6): 1044-1052). However, since the poly(A) tail is not encoded in the corresponding DNA sequence but is enzymatically added to the transcribed mature mRNA molecule, its length remains difficult to optimize.
[0005] Although the length of the poly (A) tail is known to be one of the most important physiological factors affecting mRNA stability and translation efficiency, it is difficult for the prior art to produce mRNA molecules with a determined poly (A) tail length on a large scale. For example, mRNA molecules for synthesizing proteins in therapeutic applications are mainly generated by in vitro transcription. Such methods are based on DNA templates, in which the poly (A) tail has been encoded and amplified by cloning or polymerase chain reaction (PCR). Compared with adding the poly (A) tail to the generated mRNA in an enzymatic manner, these methods theoretically have the advantage of providing a determined and reproducible length of the poly (A) tail (Holtkamp et al., 2006, Blood, 108 (13), 4009-4018). In view of the large-scale production of mRNA molecules, plasmid-based methods are particularly interesting. Plasmid production has been well established, can be easily scaled up and performed under good production specifications. Compared with PCR-based methods, the cost of plasmid production and the risk of obtaining undesirable mutations in the coding sequence of mRNA molecules are relatively low. However, there is still a major challenge in using plasmids for bacterial amplification of template DNA sequences: homopolymeric sequences (such as sequences encoding poly(A) tails) can recombine during bacterial amplification of plasmid DNA, and therefore, the sequences encoding poly(A) tails can shorten in an unpredictable manner over time (Grier et al., 2016, Mol. Ther. Nucleic Acids, 5(4): e306). Grier and colleagues reported that, for example, compared to sequences encoding poly(A) tails consisting of at least 100 nucleotides, sequences encoding 70 nucleotide long poly(A) tails remained stable, which is still shorter than the average 300 nucleotide long poly(A) tail of newly synthesized mature mRNA molecules in eukaryotes. (Grier et al., 2016, Mol. Ther. Nucleic Acids, 5(4): e306). In an attempt to increase the length of the poly(A) tail, research has focused on the use of a linear plasmid system that can stably clone sequences encoding poly(A) tails of up to 500 nucleotides (Grier et al., 2016, Mol. Ther. Nucleic Acids, 5(4): e306). Specifically, a multiple cloning site (MCS) can be used to incorporate sequences encoding mRNA molecules into a plasmid. Using unique sites for site-specific restriction enzymes, sequences encoding relatively short poly(A) tails can be added in an iterative process, thereby allowing the sequences encoding poly(A) tails contained in the amplification plasmid to be expanded. However, since the linear plasmid used is a low copy plasmid ( v2.0 Linear Cloning System ( Vector), Lucigen), it is therefore unclear how to effectively scale up this system to produce templates for in vitro transcribed mRNA on a large scale). Therefore, there remains a need for alternatives available at hand to enable large-scale delivery of templates for in vitro transcribed mRNA molecules with defined and stable poly(A) tail lengths.
[0006] The present application solves the need for in vitro transcription templates encoding mRNA molecules with defined poly(A) tail lengths and exhibiting reduced recombination of the sequence encoding the poly(A) tail during amplification in bacterial cells by providing the embodiments defined in the claims.
[0007] Specifically, the present invention relates to a DNA plasmid comprising a DNA sequence comprising (i) a first nucleotide sequence encoding an mRNA molecule and (ii) a second nucleotide sequence encoding a modified poly(A) tail located downstream thereof, wherein the second nucleotide sequence is characterized in that it consists of: (a) at least two A elements, each of which is defined as a nucleotide sequence consisting of 55 to 65 T nucleotides; and (b) at least one S element, each of which consists of: (b1) a nucleotide that is not a T nucleotide, or (b2) 2 to 10 nucleotides, preferably 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide; wherein the total number of A elements is one more than the total number of S elements, and wherein any two A elements are separated by one S element. In other words, the present invention relates to a DNA plasmid comprising a DNA sequence that can be preferably transcribed in vitro into an mRNA molecule having a modified (i.e., segmented) poly(A) tail.
[0008] Surprisingly, it was found that a DNA plasmid comprising a DNA sequence encoding an mRNA molecule with a modified poly(A) tail shows reduced recombination during amplification of said DNA plasmid in bacterial cells compared to the same DNA plasmid comprising a DNA sequence encoding the same mRNA molecule with the same poly(A) tail but without said S element.
[0009] In the context of the present invention, the terms "DNA" and "RNA" refer to single-stranded or double-stranded DNA or RNA molecules. Unless otherwise indicated, the terms "DNA" and "DNA molecule" refer to double-stranded DNA molecules consisting of A, C, G and / or T nucleotides, while the terms "RNA" and "RNA molecule" refer to single-stranded RNA molecules consisting of A, C, G and / or U nucleotides. In this article, the A, C, G, T and U nucleotides refer to nucleotides containing adenine, guanine, cytosine, thymine and uracil as their respective nitrogenous bases.
[0010] In the context of the present invention, the term "DNA plasmid" refers to a plasmid consisting of a double-stranded DNA molecule. If not otherwise specified, the term "plasmid" refers to a circular DNA molecule, but the term may also encompass linear DNA molecules. In particular, the term "plasmid" also encompasses molecules obtained by linearizing a circular plasmid, for example by cutting it with a restriction enzyme, thereby converting the circular plasmid molecule into a linear molecule. Plasmids can replicate, i.e. amplify in cells independently of the genetic information stored as chromosomal DNA, and can be used for cloning, i.e. for amplifying genetic information in bacterial cells. Preferably, the DNA plasmid according to the present invention is a medium-copy or high-copy plasmid, more preferably a high-copy plasmid. Examples of such high-copy plasmids are vectors based on pUC, pTZ plasmid or any other plasmid containing a replication origin that supports high copy numbers of the plasmid (eg pMB1, pCoIE1).
[0011] Plasmid according to the present invention preferably comprises at least an origin of replication (ORI), a marker gene or its fragment and / or a reporter gene or its fragment and a unique restriction site allowing insertion of DNA elements, preferably a restriction site in the form of a multiple cloning site (MCS). ORI is essential for replication. Marker genes such as antibiotic resistance genes are conducive to identifying cells containing plasmids comprising the marker gene. Reporter genes (such as lacZ or luciferase) are conducive to measuring the intensity and / or regulation of target gene expression connected thereto, or they can be used as alternative target genes to test expression and / or establish new methods or systems. MCS is included in several restriction sites with uniqueness in DNA plasmids, and each restriction site is specifically recognized by restriction enzymes. Specifically, MCS is conducive to genetic elements, such as DNA sequence according to the present invention or the second nucleotide sequence being incorporated into suitable DNA plasmids, preferably in high-copy DNA plasmids. In the latter case, the DNA plasmid also comprises a target gene (encoding mRNA) connected with a modified poly (A) encoded by the second nucleotide sequence.
[0012] Double-stranded DNA molecules (such as DNA plasmids) are composed of two complementary DNA chains. The term "complementary" refers to nucleotides whose nitrogen bases can naturally bind to each other through hydrogen bonds, i.e. A and T nucleotides, A and U nucleotides, and C and G nucleotides. According to the present invention, one of the two chains of a double-stranded DNA molecule comprises a "DNA sequence". In this article, the term "DNA sequence" refers to a part of one chain of a double-stranded DNA molecule (such as a DNA plasmid). According to the present invention, the DNA sequence is composed of A, C, G and T nucleotides and comprises a first nucleotide sequence and a second nucleotide sequence as defined herein.
[0013] In the context of the present invention, the "first nucleotide sequence" contained in the DNA sequence is a "nucleotide sequence encoding an mRNA molecule". In other words, the first nucleotide sequence refers to the portion of the DNA sequence that can be used as a template during transcription (i.e., the synthesis of mRNA molecules). Therefore, in the case of transcribing an "mRNA molecule" from a first nucleotide sequence, the mRNA has a nucleotide sequence complementary to the first nucleotide sequence, except that U nucleotides are used instead of T nucleotides to synthesize the mRNA molecule. Since the poly (A) tail is not naturally encoded in the DNA sequence, but is enzymatically added to the mRNA molecule during and / or after transcription, the term "nucleotide sequence encoding an mRNA molecule" refers to the portion of the DNA sequence that can be used as a template during transcription of an mRNA molecule without any poly (A) tail.
[0014] As used herein, "encoding" or "encode" refers to i) the genetic information contained in a DNA sequence that can be transcribed into an mRNA molecule, and / or ii) the genetic information contained in an mRNA molecule that can be translated into an amino acid sequence. Thus, these terms also encompass the genetic information contained in DNA that can be converted into an amino acid sequence (e.g., a protein) by transcribing an mRNA molecule.
[0015] In this article, the terms "mRNA molecule" and "mRNA" are used interchangeably and refer to a class of RNA molecules, preferably a single-stranded sequence consisting of A, C, G and U nucleotides that contains one or more coding sequences. The one or more coding sequences can be used as a template during translation of the amino acid sequence synthesis process. In other words, the term "mRNA" should be understood to refer to any RNA molecule that is suitable for expressing an amino acid sequence or can be translated into an amino acid sequence (such as a protein).
[0016] Other features of the first nucleotide sequence encoding the mRNA molecule and other features of the encoded mRNA molecule are described in further detail below.
[0017] According to the present invention, the first nucleotide sequence contained in the DNA sequence contained in the DNA plasmid is followed by the second nucleotide sequence contained in the DNA sequence, that is, the second nucleotide sequence is located downstream of the first nucleotide sequence. In other words, the two sequences are located on the same strand of the single-stranded or double-stranded DNA molecule, so that in the case of transcription, the first nucleotide sequence is transcribed first, and then the second nucleotide sequence is transcribed.
[0018] In some embodiments, the first nucleotide sequence is directly connected to the second nucleotide sequence, i.e., there is no intervening nucleotide. However, the first and second nucleotide sequences can be separated by intervening nucleotides. Preferably, the first and second nucleotide sequences are separated by no more than 100 nucleotides, more preferably no more than 50, 40 or 30 nucleotides, and most preferably no more than 20, 10 or 5 nucleotides.
[0019] According to the present invention, the DNA sequence of the DNA plasmid comprises a first nucleotide sequence and a second nucleotide sequence located downstream thereof. The "second nucleotide sequence" is a "nucleotide sequence encoding a modified poly (A) tail". In this article, this refers to a portion of the DNA sequence that can be used as a template for synthesizing a modified poly (A) tail during transcription of the DNA sequence (preferably during in vitro transcription). The naturally occurring poly (A) tail enzymatically added to the pre-mature mRNA molecule is generally composed of A nucleotides. This naturally occurring poly (A) tail is also referred to as a conventional poly (A) tail hereinafter.
[0020] According to the present invention, the term "modified poly (A) tail" refers to a segmented poly (A) tail comprising nucleotides other than A nucleotides. Specifically, the second nucleotide sequence encoding the modified poly (A) tail according to the present invention is characterized in that it consists of: (a) at least two A elements, each A element is defined as a nucleotide sequence consisting of 35 to 65 T nucleotides, preferably 55 to 65 T nucleotides; and (b) at least one S element, each S element consists of: (b1) one nucleotide that is not a T nucleotide, or (b2) 2 to 10 nucleotides, preferably 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide; wherein the total number of A elements is one more than the total number of S elements, and wherein any two A elements are separated by one S element.
[0021] According to the present invention, the A elements and the S elements are arranged alternately in the second nucleotide sequence. Therefore, the term "wherein any two A elements are separated by an S element" is intended to be understood as "wherein any two consecutive A elements are separated by an S element". For illustration, in the case of three A elements and two S elements, the second sequence according to the present invention consists of: one (i.e., first) A element; one S element; another (i.e., second) A element; another S element; and yet another (i.e., third) A element. Therefore, in this example, the term "any two A elements" refers to the first and second A elements and the second and third A elements, rather than the first and third A elements. Therefore, the term refers to any one of at least two A elements and the closest A element among the remaining A elements.
[0022] In some embodiments, the DNA sequence according to the present invention comprises a first nucleotide sequence, followed by a second nucleotide sequence, followed by one or more additional nucleotides other than T nucleotides. The additional nucleotides are preferably 1 to 5 C nucleotides, more preferably 1 C nucleotide. In other words, the DNA sequence can encode an mRNA molecule, a modified poly (A) tail, and additional nucleotides, preferably one G nucleotide.
[0023] As shown in the attached examples, it has been found that the use of a DNA plasmid according to the invention comprising a DNA sequence comprising a first and a second nucleotide sequence encoding an mRNA molecule and a modified poly(A) tail results in reduced recombination during amplification of said DNA plasmid in bacterial cells, compared to an identical DNA plasmid but having a second nucleotide sequence encoding an unmodified poly(A) tail consisting of the same total number of A nucleotides as encoded by the second nucleotide sequence according to the invention. In other words, the use of a DNA plasmid according to the invention results in reduced recombination during amplification of said DNA plasmid in bacterial cells, compared to an identical DNA plasmid but without said at least one S element between said at least two A elements.
[0024] Surprisingly, it was also observed at the same time that the stability and translation efficiency of polyribonucleotides transcribed from the DNA sequences according to the invention are generally not negatively affected by the modified poly(A) tail as defined above.
[0025] In this article, the term "recombination" refers to homologous recombination, wherein the nucleotide sequence is exchanged between two highly similar or identical nucleotide sequences contained in, for example, a DNA molecule (such as a DNA plasmid and / or a chromosome). The term "recombination" includes intramolecular homologous recombination events, i.e., the recombination of two highly similar or identical nucleotide sequences contained in the same DNA molecule. In the context of the present invention, this specifically refers to the recombination of another highly similar or identical nucleotide sequence contained in the same DNA plasmid by encoding a nucleotide sequence of a modified poly (A) tail and a conventional poly (A) tail, and / or refers to the recombination of two terminal parts of such a nucleotide sequence. Alternatively or additionally, the term "recombination" includes an intermolecular homologous recombination event between a nucleotide sequence encoding a modified poly (A) tail and a conventional poly (A) tail contained in a DNA plasmid and a highly similar or identical nucleotide sequence contained in another DNA molecule (e.g., another DNA plasmid contained in the same cell).
[0026] According to the present invention, the term "reduced recombination" means that the recombination is reduced by at least 5%, preferably by at least 10%, more preferably by at least 25%, even more preferably by at least 50%, and most preferably by at least 100%.
[0027] Recombination reduction can be determined, for example, by the following procedure: genetically identical bacterial cells are used to amplify DNA plasmids according to the present invention (Group I) and are used to amplify DNA plasmids (Group II) that are identical except that the second nucleotide sequence does not include at least one S element. Using conventional laboratory procedures, bacterial cells can be lysed when amplified, DNA plasmids are obtained and linearized, and the DNA sequence or the second nucleotide sequence contained is purified. Then, for example, by sequencing and / or electrophoresis (such as gel electrophoresis or capillary electrophoresis), the DNA sequence obtained, particularly the second nucleotide sequence obtained, can be qualitatively studied with regard to nucleotide composition, sequence, and / or length. Alternatively or additionally, the occurrence and frequency of recombination can be quantitatively determined by measuring the length of the second nucleotide sequence, calculating the ratio of the second nucleotide sequence with the expected length defined by the second nucleotide sequence used initially to the total number of second nucleotide sequences in each group, and comparing the ratio obtained by each group between each group. Alternatively, before studying the length of the poly (A) tail transcribed in and between Group I and Group II as described above, the DNA sequence extracted can be transcribed in vitro.
[0028] For DNA plasmids comprising the second nucleotide sequence according to the present invention, a reduction in such recombination has been observed. Specifically, it has been observed, for example, that the S element consisting of a single nucleotide is advantageous for reducing recombination during bacterial amplification. Therefore, in a particularly preferred embodiment of the present invention, the DNA plasmid comprises a first nucleotide sequence encoding an mRNA molecule and a second nucleotide sequence encoding a modified poly (A) tail, wherein any one of the S elements consists of a C nucleotide or an A nucleotide, preferably consists of a C nucleotide.
[0029] In some embodiments, the second nucleotide sequence according to the present invention consists of two A elements separated by one A nucleotide. More preferably, the two A elements are separated by one C nucleotide.
[0030] In some embodiments, the second nucleotide sequence according to the present invention consists of three A elements, wherein any two A elements are separated by one A nucleotide. Preferably, any two of the three A elements are separated by one C nucleotide.
[0031] In some embodiments, the second nucleotide sequence according to the present invention consists of four A elements, wherein any two A elements are separated by one A nucleotide. Preferably, any two of the four A elements are separated by one C nucleotide.
[0032] In some embodiments, the second nucleotide sequence according to the present invention consists of five A elements, wherein any two A elements are separated by one A nucleotide. Preferably, any two of the five A elements are separated by one C nucleotide.
[0033] In some embodiments, the second nucleotide sequence according to the present invention consists of six A elements, wherein any two A elements are each separated by one A nucleotide. Preferably, any two of the six A elements are separated by one C nucleotide.
[0034] In some embodiments, the second nucleotide sequence according to the present invention consists of seven A elements, wherein any two A elements are separated by one A nucleotide. Preferably, any two of the seven A elements are separated by one C nucleotide.
[0035] In some embodiments, the second nucleotide sequence according to the present invention consists of eight A elements, wherein any two A elements are separated by one A nucleotide. Preferably, any two of the eight A elements are separated by one C nucleotide.
[0036] In the case where more than one S element is included in the second nucleotide sequence, the at least two S elements may have the same sequence or their sequences may vary. Preferably, the at least two S elements each consist of i) the same nucleotide in the case of one nucleotide, or ii) the same nucleotide sequence in the case of 2 to 10 nucleotides, preferably 6 nucleotides.
[0037] Therefore, in some embodiments, each of the at least one S element contained in the second nucleotide sequence according to the present invention consists of A nucleotides. Preferably, each of the at least one S element contained in the second nucleotide sequence according to the present invention consists of C nucleotides.
[0038] In some embodiments, in the case of at least two S elements, at least one but not all of the S elements may consist of A nucleotides, and each of at least one of the remaining S elements may consist of i) one G, or preferably of C nucleotides, or of ii) 2 to 10 nucleotides, preferably 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide.
[0039] In some embodiments, in the case of at least two S elements, at least one but not all of the S elements are preferably composed of G nucleotides, and each of the at least one remaining S element may be composed of i) A or C nucleotides, or ii) 2 to 10 nucleotides, preferably 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide.
[0040] In some embodiments, the number of A elements contained in the nucleotide sequence encoding the modified poly(A) tail contained in the DNA sequence of the DNA plasmid as defined above is two, three or four. In other words, in a particularly preferred embodiment, the second nucleotide sequence encoding the modified poly(A) tail consists of: i) two A elements flanking one S element, ii) three A elements in alternating order with two S elements, or iii) four A elements in alternating order with three S elements; the A elements and S elements defined above.
[0041] In some embodiments, the second nucleotide sequence encoding a modified poly (A) tail consists of two A elements and one S element in alternating order, each A element consists of the same number of T nucleotides, and the S element consists of: i) 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide; or preferably, ii) C nucleotides.
[0042] In some embodiments, the second nucleotide sequence encoding a modified poly (A) tail consists of three A elements and two S elements in alternating order, each A element consisting of the same number of T nucleotides, wherein all of the two S elements are each composed of: i) 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide; or preferably, ii) C nucleotides.
[0043] In some embodiments, the second nucleotide sequence encoding a modified poly (A) tail consists of four A elements and three S elements in alternating order, each A element consisting of the same number of T nucleotides, wherein all of the three S elements are each composed of: i) 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide; or preferably, ii) C nucleotides.
[0044] In some embodiments, the second nucleotide sequence encoding a modified poly (A) tail consists of two, three, or four A elements, respectively, alternating with one, two, or three S elements, wherein at least two of the A elements differ in the number of T nucleotides thereof, wherein all of the S elements each consist of: i) 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide.
[0045] In some embodiments, the second nucleotide sequence encoding a modified poly (A) tail consists of two, three, or four A elements alternating with one, two, or three S elements, respectively, wherein at least two of the A elements differ in the number of T nucleotides, wherein preferably all of the S elements are each composed of one C nucleotide.
[0046] In some embodiments of the DNA plasmid as defined above, the number of A elements is four, and the nucleotide sequences of the four A elements together have a total length of 240 nucleotides.
[0047] Preferably, each A element has a length of 60 nucleotides. In other words, in a particularly preferred embodiment, the second nucleotide sequence encoding the modified poly (A) tail consists of four A elements and three S elements in an alternating order, wherein the four A elements together consist of 240 nucleotides and preferably each have the same length.
[0048] More preferably, the second nucleotide sequence encoding the modified poly (A) tail consists of four A elements and three S elements in alternating order, each A element consists of 60 T nucleotides, wherein all three S elements are each composed of: i) 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide; or preferably, ii) one C nucleotide.
[0049] In some embodiments of the DNA plasmid as defined above, the number of the A element is two, and the nucleotide sequences of the two A elements together have a total length of 120 nucleotides.
[0050] Preferably, each A element has a length of 60 nucleotides. In other words, in a particularly preferred embodiment, the second nucleotide sequence encoding the modified poly (A) tail consists of two A elements with a total length of 120 nucleotides together. In other words, in a particularly preferred embodiment, the second nucleotide sequence encoding the modified poly (A) tail consists of two A elements and one S element in an alternating order, wherein the two A elements together consist of 120 nucleotides and preferably each have the same length.
[0051] More preferably, the second nucleotide sequence encoding a modified poly (A) tail consists of two A elements flanked by an S element, each A element consisting of 60 T nucleotides, and the S element consists of the following: i) 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide; or preferably, ii) a C nucleotide.
[0052] In some embodiments of the DNA plasmid as defined above, the DNA plasmid comprises three A elements with a total length of 120 nucleotides together in the nucleotide sequence encoding the modified poly (A) tail. In other words, in this embodiment of the DNA plasmid as defined above, the number of A elements is three, and the nucleotide sequence of these three A elements together has a total length of 120 nucleotides, preferably each A element has a length of 40 nucleotides. Therefore, the second nucleotide sequence encoding the modified poly (A) tail can be composed of three A elements and two S elements in an alternating order. Preferably, each of the three A elements consists of 40 T nucleotides, and each of the two S elements consists of: i) preferably, one C nucleotide; or ii) 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide.
[0053] According to the present invention, the DNA plasmid comprises a DNA sequence, and this DNA sequence comprises the first nucleotide sequence as defined above, followed by the second nucleotide sequence.Preferably, before the first nucleotide sequence is the promoter comprised in the DNA sequence or the DNA plasmid.Promoter participates in the transcription of the nucleotide sequence (such as the DNA sequence or the first nucleotide sequence comprising the first nucleotide sequence) behind the control and initiation.Therefore, the promoter comprised in the DNA plasmid, preferably a strong promoter, can be favourable for comparing other genetic elements to the transcription duration and / or the influence of intensity of the nucleotide sequence encoding the mRNA molecule behind.On the other hand, the promoter comprised in the DNA sequence, preferably a strong promoter, can be favourable for the transcription duration and / or the intensity of the nucleotide sequence encoding the mRNA molecule behind the optimization.
[0054] The promoter comprises at least one recognition site, followed by a binding site. The recognition and binding sites can interact with the amino acid sequence that mediates or regulates transcription. Compared with the recognition site, the binding site is closer to the first nucleotide sequence included in the DNA sequence of the present invention. For example, the recognition site can be a -35 box, and the binding site can be a -10 box, which is located at a distance of about 35 nucleotides and 10 nucleotides before the transcription start site. The binding site can be, for example, a Pribnow box in a prokaryotic organism and a TATA box in a eukaryotic organism. Preferably, the binding site is a Pribnow box contained in a DNA plasmid or a DNA sequence near the first nucleotide sequence.
[0055] Optionally, the promoter comprises at least one additional regulatory element, such as an AT-rich upstream element located about 40 and / or 60 nucleotides before the transcription start site, and / or an additional regulatory element that enhances promoter activity located between the recognition site and the binding site.
[0056] In a particularly preferred embodiment, the promoter is a strong promoter. In other words, the promoter comprises a sequence that promotes transcription of the following DNA sequence according to the present invention. Strong promoters are known to those skilled in the art, such as OXB18, OXB19 and OXB20 promoters derived from the RecA promoter of Escherichia coli, or can be identified or synthesized by routine laboratory procedures.
[0057] Optionally, the promoter is preceded by additional regulatory elements such as enhancers contained in the DNA plasmid which promote the transcription of the DNA sequence according to the invention.
[0058] The DNA sequence comprises a first nucleotide sequence encoding an mRNA molecule, i.e., a first nucleotide sequence that can be converted into an mRNA molecule during transcription, wherein the synthesis of the mRNA molecule starts with its 5' end and ends with its 3' end. The characteristics of the first nucleotide sequence encoding an mRNA molecule are described in more detail below in conjunction with the encoded mRNA molecule.
[0059] The first nucleotide sequence comprises at least one region encoding an untranslated region (UTR) and at least one coding region. Preferably, the first nucleotide sequence encodes at least a 5'UTR and the coding region of the encoded mRNA molecule. The coding region may include a non-coding portion and a coding portion. Preferably, the coding region consists of at least one coding portion, which encodes a portion of the mRNA molecule that can be translated into an amino acid sequence or a portion thereof.
[0060] In a particularly preferred embodiment, the first nucleotide sequence comprises a region encoding a 5'UTR, followed by a coding region, followed by a region encoding a 3'UTR of the encoded mRNA molecule.
[0061] According to the present invention, the first nucleotide sequence encodes an mRNA molecule. Preferably, the first nucleotide sequence encodes an mRNA comprising a 5'UTR, a coding sequence and a 3'UTR.
[0062] The 5' end of 5'UTR is defined by the transcription start site, and the 3' end is followed by the coding sequence. The ends of the coding sequence are the start codon and the stop codon, i.e., the first three nucleotides and the last three nucleotides that can be translated of the mRNA molecule, respectively. The 3'UTR begins after the stop codon of the coding sequence, followed by a modified poly (A) tail encoded by the second nucleotide sequence according to the present invention.
[0063] The 5'UTR typically contains at least one ribosome binding site (RBS), such as the Shine-Dalgarno sequence in prokaryotes and the Kozak sequence or translation initiation site in eukaryotes. The RBS promotes efficient and accurate translation of mRNA molecules by recruiting ribosomes at the start of translation. The activity of a given RBS can be optimized by changing its length and sequence and the distance from the start codon. Optionally or optionally, the 5'UTR includes an internal ribosome entry site or IRES.
[0064] In some embodiments, the mRNA molecule comprises a 5'UTR, which additionally comprises one or more additional regulatory sequences, such as binding sites for amino acid sequences that enhance the stability of the mRNA molecule, binding sites for amino acid sequences that enhance the translation of the mRNA molecule, regulatory elements (such as riboswitches), binding sites for regulatory RNA molecules (such as miRNA molecules), and / or nucleotide sequences that positively affect the initiation of translation. In addition, within the 5'UTR, preferably there is no functional upstream open reading frame, an out-of-frame upstream translation initiation site, an out-of-frame upstream start codon, and / or a nucleotide sequence that produces a secondary structure that reduces or prevents translation. The presence of such nucleotide sequences in the 5'UTR can have a negative impact on translation.
[0065] The coding sequence is encoded by at least one coding portion of the first nucleotide sequence and comprises codons that can be translated into an amino acid sequence. Other features of the encoded amino acid sequence are described in detail below.
[0066] The coding sequence can comprise the codon of naturally occurring coding sequence, or it can be a partially or completely synthesized coding sequence. Alternatively, the coding sequence can be a partially or completely codon-optimized sequence derived from a native sequence to be used. Most amino acids are encoded by more than one codon, i.e. three continuous nucleotides that can be translated into amino acids of mRNA molecules. The codons that are preferentially used for a given amino acid in some species exist. Compared with the mRNA molecules that are identical but comprise equally rare codons, the presence of codons that occur more often can increase the amount of the amino acid sequence translated based on a given mRNA molecule. Therefore, by avoiding rare codons and increasing the appearance of the abundant codons of a given amino acid to improve the translation of the mRNA, it is advantageous to adapt species-specifically to the codons in a given coding sequence.
[0067] The mRNA may optionally further comprise a 3'UTR. The 3'UTR may comprise one or more regulatory sequences, such as binding sites for amino acid sequences that enhance the stability of the mRNA molecule, binding sites for regulatory RNA molecules (such as miRNA molecules), and / or signal sequences involved in the intracellular transport of the mRNA molecule.
[0068] In a particularly preferred embodiment, the mRNA molecule encoded by the first nucleotide sequence comprises a 5'UTR with at least one RBS and / or IRES, a coding sequence with optimized codons, and a 3'UTR with at least one regulatory sequence as defined above.
[0069] MRNA molecule according to the present invention comprises coding sequence, i.e. the sequence of encoding amino acid sequence. About the function of the amino acid sequence encoded, there is no restriction, and further describes the possible amino acid sequence encoded by the polyribonucleotide below. In this article, the term "amino acid sequence" encompasses any kind of amino acid sequence, i.e. two or more amino acid whose chains are connected via peptide bonds and refers to any target amino acid sequence. Preferably, the amino acid sequence encoded is at least 5 amino acids long, more preferably at least 10 amino acids long, even more preferably at least 50,100,200 or 500 amino acids long. In other words, the term "amino acid sequence" encompasses short peptides, oligopeptides, polypeptides, fusion proteins, proteins and fragments thereof, such as the part of known proteins, preferably functional parts. These can be, for example, the biologically active part of protein or the antigenic part that can effectively produce antibodies, such as epitopes.
[0070] Preferably, the function of the amino acid sequence encoded in or near the cell is necessary or beneficial, for example, such an amino acid sequence: in or near the cell, the missing or defective form of the amino acid sequence induces disease or discomfort, and its provision can alleviate or prevent disease or discomfort; or such an amino acid sequence: in or near the cell, the amino acid sequence can promote a process that is beneficial to the body. The encoded amino acid sequence can encode an amino acid sequence that acts as a factor, inducer, regulator, stimulator or enzyme, or a functional fragment thereof, wherein this amino acid sequence is an amino acid sequence whose function is necessary to compensate for a disorder (especially a metabolic disorder) or to initiate a process in the body (such as the formation of new blood vessels, tissues, etc.). Here, a functional variant is understood to mean such a fragment: it can assume the function of an amino acid sequence in a cell, the function of the amino acid sequence is necessary in a cell, or the missing or defective form of the amino acid sequence is pathogenic.
[0071] Preferably, for supplementary or medical purposes, it is advantageous to produce or regenerate such an amino acid sequence that has a physiological function caused by the biosynthesis of a suboptimal amino acid sequence, and therefore also advantageously directly or indirectly affects the course of the disease. Disorders with a known genetic basis are, for example, cystic fibrosis, hemophilia, hypertension, elevated cholesterol levels, cancer, neurodegenerative disorders, mental illness, etc. An online catalog can be obtained at the ONIM (Online Mendelian Inheritance in Man) website (http: / / onim.org), with 22,993 human genes and genetic disorder entries and descriptions of their corresponding genes and their phenotypes; each sequence can be obtained from the Uniprot database (http: / / www.uniprot.org). As a non-limiting example, Table 1 below lists some congenital diseases and corresponding genes (one or more). Due to the high degree of interaction of cell signaling pathways, mutations in certain genes cause a variety of pathogenic symptoms, of which only the characteristic symptoms are listed in Table 1.
[0072] Table 1
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079] The protein by polyribonucleotide encoding according to the present invention can also have the potentiality of inducing the immunogenic response that for example serves as antigen.Therefore, polyribonucleotide according to the present invention makes itself available for supplementary purpose or medical purpose, comprises vaccination.
[0080] The suitable nucleotide sequence of above-mentioned genetic elements, such as UTR, regulating sequence and binding site, is the nucleotide sequence that strengthens the effect of mRNA molecule and / or the duration of action. Such nucleotide sequence as above and coding region and / or coding sequence can be naturally occurring, mutagenic or synthetic nucleotide sequence or its combination, and can identify and reorganize by routine experiments well known to persons skilled in the art.
[0081] The present invention further relates to bacterial host cells comprising the above-mentioned DNA plasmids. DNA plasmids according to the present invention can be stored and / or amplified in competent bacterial host cells for transformation. Competent host cells are cells with the ability to absorb free extracellular genetic material (such as DNA plasmids) independently of their sequences. Natural competent bacteria have the ability to use, for example, receptor proteins or protein complexes to bind extracellular genetic material. In addition, the cell has the ability to use, for example, peptides, proteins or protein complexes (such as DNA translocases) to transfer genetic material from the extracellular space into cells. Various bacterial cells known to those skilled in the art are naturally able to absorb exogenous DNA from the environment, so they can serve as bacterial host cells according to the present invention. In addition, competent bacterial host cells can be obtained from natural non-competent bacterial cells using, for example, electroporation or chemicals (such as calcium ion treatment and accompanied by high temperature exposure). After uptake, the DNA plasmid is preferably neither degraded nor integrated in the genomic information of the bacterial host cell.
[0082] Bacterial host cells include Escherichia coli (E. coli) cells known to those skilled in the art. In E. coli cells, the integration of extracellular genetic material into the genetic material of the host cell can be carried out by a RecA-dependent process, i.e., a process that depends on the RecA protein. This protein is essential for the repair and maintenance of DNA and is involved in homologous recombination. Therefore, in some embodiments, the bacterial host cell according to the present invention is an E. coli cell, preferably an E. coli recA - It may be advantageous to avoid integration of the genetic information contained in the DNA plasmid according to the invention into the original genetic material of the E. coli cells.
[0083] The present invention further relates to the use of a nucleotide sequence encoding a modified poly(A) tail as defined above, wherein said nucleotide sequence is located downstream of a nucleotide sequence encoding an mRNA molecule, for the preparation of a DNA plasmid showing reduced recombination during amplification in a bacterial host cell.
[0084] The DNA plasmid according to the present invention can be prepared by methods known to those skilled in the art. Preferably, the MCS contained in the DNA plasmid is cut using a site-specific restriction enzyme, and the resulting DNA plasmid end is connected to the end of the DNA sequence. Therefore, the DNA sequence according to the present invention preferably becomes an end at two sites through the MCS.
[0085] Regarding the nucleotide sequence encoding the modified poly (A) tail, the nucleotide sequence encoding the mRNA molecule, the DNA plasmid, and the reduction of recombination during the amplification of the DNA plasmid in the bacterial host cell, the same as described above in conjunction with the DNA plasmid and the DNA sequence according to the present invention, applies. In addition, other features of this DNA plasmid and the DNA sequence may also be as described above.
[0086] The present invention further relates to the use of the nucleotide sequence encoding a modified poly (A) tail as defined above to reduce recombination during DNA plasmid amplification in bacterial host cells. In other words, compared with the same DNA plasmid but with a conventional poly (A) tail encoding, specifically compared with the same DNA plasmid in which the nucleotide sequence encoding the poly (A) tail does not include any S elements, the nucleotide sequence encoding a modified poly (A) tail as defined above can be used to reduce recombination during DNA plasmid amplification containing the nucleotide sequence in bacterial cells. The DNA plasmid is preferably a plasmid comprising a nucleotide sequence encoding an mRNA molecule, wherein the nucleotide sequence encoding the modified poly (A) tail is located downstream of the nucleotide sequence encoding the mRNA molecule. It is particularly advantageous to reduce the recombination of the plasmid by replacing the nucleotide sequence encoding the conventional poly (A) tail with the nucleotide sequence encoding the modified poly (A) tail as described above.
[0087] About the nucleotide sequence of coding modified poly (A) tail, the nucleotide sequence of coding mRNA molecule, DNA plasmid, and the reduction of recombination during the amplification of said DNA plasmid in bacterial host cell, the same as the description made by it in conjunction with the DNA plasmid according to the present invention above applies. In addition, other features of this DNA plasmid also can be as described above.
[0088] The present invention further relates to a method for reducing the recombination of a DNA plasmid comprising a DNA sequence encoding an mRNA molecule and a poly(A) tail located downstream thereof during amplification in a bacterial host cell, wherein the reduction is achieved by replacing the part of the DNA sequence encoding the poly(A) tail by a nucleotide sequence encoding a modified poly(A) tail as defined above.
[0089] The replacement of the part of the DNA sequence can be carried out, for example, using an MCS that is located at the part flank of the DNA sequence and is located at the flank of the nucleotide sequence for replacement. Therefore, the DNA plasmid can be cut using a restriction enzyme at the MCS, and the obtained fragments can be studied using, for example, capillary electrophoresis or gel electrophoresis. Using the MCS, the part of the DNA plasmid that does not contain the DNA sequence encoding the poly (A) tail can then be connected to the nucleotide sequence encoding the modified poly (A) tail.
[0090] About the nucleotide sequence encoding the modified poly (A) tail, the nucleotide sequence encoding the mRNA molecule, the DNA plasmid, and the reduction of recombination during the amplification of the DNA plasmid in the bacterial host cell, the same as described above in conjunction with the DNA plasmid according to the present invention applies. In addition, the other features of this DNA plasmid may also be as described above.
[0091] The present invention further relates to a method for producing polyribonucleotides, said polyribonucleotides comprising a sequence encoding an amino acid sequence and a modified poly (A) tail encoded by the nucleotide sequence defined above, said method comprising the step of producing said polyribonucleotides by in vitro transcription from a DNA plasmid according to the present invention.
[0092] In this article, term " polyribonucleotide " refers to single-stranded RNA molecule.Polyribonucleotide according to the present invention comprises mRNA molecule encoded by the first nucleotide sequence and modified poly (A) tail encoded by the second nucleotide sequence.In other words, polyribonucleotide comprises 5'UTR, coding sequence, optionally 3'UTR and modified poly (A) tail.
[0093] In a particularly preferred embodiment, the polyribonucleotide comprises a 5'UTR with at least one RBS and / or IRES, a coding sequence with an optimized codon, optionally a 3'UTR with at least one regulating and controlling sequence and a modified poly (A) tail. Optionally, the polyribonucleotide is included in other nucleotides except the A nucleotides after the modified poly (A) tail, preferably a G nucleotide. This can, for example, extend its lifespan when the polyribonucleotide produced is introduced into the cell, thereby extend the duration of its effect.
[0094] With regard to the 5'UTR, coding sequence, 3'UTR, and modified poly(A) tail, the same as described above applies. In addition, other features of such genetic elements may also be as described above.
[0095] Polyribonucleotides according to the present invention can be produced by any method known in the art.Preferably, use DNA sequence according to the present invention as template in vitro transcription of polyribonucleotides.In vitro transcription requires linear DNA template, ribonucleoside triphosphate, buffer system and suitable RNA polymerase (such as T7 RNA polymerase) of the purification comprising promoter.Therefore, usually obtain and purify according to DNA plasmids of the present invention by cell lysis.Then, for example, using site-specific restriction enzymes, i) before the promoter before the first nucleotide sequence and ii) immediately after the second nucleotide sequence of the modified poly (A) tail of the coding, or when other nucleotides are not T nucleotides, immediately after the other nucleotides (preferably after a C nucleotide) cutting the purified DNA plasmid.Then, using standard laboratory protocols, in the presence of A, C, G and U nucleotides, the linear template sequence obtained is used for the in vitro transcription of polyribonucleotides according to the present invention.When at position i) and ii) when cutting templates, the template used for transcription is just as ends with desired modified poly (A) tails or desired non-T nucleotides. Therefore, it is possible to use an RNA polymerase with or without the ability to terminate transcription, for example, at a given position, thereby causing run-off transcription. Therefore, cutting the DNA plasmid at positions i) and ii) and using the resulting nucleotide sequence as a transcription (preferably in vitro transcription) template ensures that the synthesis of a modified poly (A) tail comprising an mRNA molecule and a defined length according to the present invention is achieved. The quantity and quality of the polyribonucleotides transcribed in vitro can be measured, for example, by spectrophotometry, capillary electrophoresis and / or sequencing.
[0096] In a preferred embodiment, the polyribonucleotide produced is further modified by enzymatically adding a 5' cap (such as a C1-m7G cap or a m7GpppG cap). This can be advantageous for regulating and / or extending the duration of action of the polyribonucleotide in the cell.
[0097] In some embodiments of the present invention, polyribonucleotide is produced by carrying out in vitro transcription under the existence of unmodified and / or modified nucleotide.In other words, polyribonucleotide as above can at least use the nucleotide sequence that comprises the nucleotide sequence of coding mRNA molecule and the DNA sequence of the nucleotide sequence of coding according to modified poly (A) tail of the present invention as template, uses unmodified and / or modified nucleotide to synthesize by in vitro transcription.
[0098] The term " unmodified nucleotide " used herein refers to A, C, G, T and U nucleotide as above.Particularly, in the case of the in vitro transcription of polyribonucleotide, the term refers to A, C, G and U nucleotide.Four kinds of back are referred to as four kinds of nucleotide types that comprise in the polyribonucleotide in this article.
[0099] The term "modified nucleotide" as used herein refers to any naturally occurring or chemically synthesized isomer of A, C, G, T and U nucleotides, and refers to any naturally occurring or chemically synthesized analogs, alternatives or modified nucleotides or isomers thereof having, for example, chemical modifications or substituted residues. The modified nucleotides may have base modifications and / or sugar modifications. The modified nucleotides may also have, for example, phosphate group modifications of the five main caps of polyribonucleotides containing protein-encoding sequences. Modified nucleotides also include nucleotides synthesized after transcription by covalent modification of nucleotides. In addition, any suitable mixture of unmodified and modified nucleotides is possible. Examples of non-limiting numbers of modified nucleotides can be found in the literature (e.g., Cantara et al., Nucleic Acids Res, 2011, 39 (Issue suppl_1): D195-D201; Helm and Alfonzo, Chem Biol, 2014, 21 (2): 174-185;Carell et al., Angew Chem Int Ed Engl, 2012, 51(29):7110-31), and based on their respective nucleoside residues, some preferred modified nucleotides are exemplarily listed below: 1-methyladenosine, 2-methylthio-N6-hydroxynorvalyl carbamoyladenosine, 2-methyladenosine, 2-O-ribosylphosphate adenosine, adenosine), N6-methyl-N6-threonylcarbamoyladenosine, N6-acetyladenosine, N6-glycinylcarbamoyladenosine, N6-isopentenyladenosine, N6-methyladenosine, N6-threonylcarbamoyladenosine, N6,N6-dimethyladenosine, N6-(cis-hydroxyisopentenyladenosine)adenosine, N6-hydroxynorvalylcarbamoyladenosine, 1,2-O-dimethyladenosine, N6,2-0-dimethyladenosine, 2-0-methyladenosine, N6,N6,0-2-trimethyladenosine, 2-methylthio-N6-(cis-hydroxy isopentenyl)adenosine, 2-methylthio-N6-methyladenosine, 2-methylthio-N6-isopentenyladenosine, 2-methylthio-N6-threonylaminoformyladenosine, N6-2-methylthio-N6-threonylaminoformyladenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, 7-methyladenosine, 2-methylthio-adenosine, 2-methoxy-adenosine, 2'-amino- 2'-deoxyadenosine, 2'-azido-2'-deoxyadenosine, 2'-fluoro-2'-deoxyadenosine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenosine, 7-deaza-8-aza-adenosine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-2,6-diaminopurine;2-thiocytidine, 3-methylcytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-methylcytidine, 5-hydroxymethylcytidine, 5-hydroxycytidine, lysine, N4-acetyl-2-0-methylcytidine, 5-formyl-2-0-methylcytidine, 5,2-O-dimethylcytidine, 2-O-methylcytidine, N4,2-0-dimethylcytidine, N4,N4,2-0-trimethylcytidine, isocytidine, pseudocytidine, pseudoisocytidine, 2-thio-cytidine, 2'-methyl-2'-deoxycytidine, 2-amino-2'-deoxycytidine, 2'-fluoro-2'-deoxycytidine, 5-iodocytidine, 5-bromocytidine and 2'-azido-2'-deoxycytidine, 2'-amino-2'-deoxycytidine, 2'-fluoro-2'-deoxycytidine, 5-azacytidine, 3-methyl-cytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio- 1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-cytidine-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine; 1-methylguanosine , N2,7-dimethylguanosine, N2-methylguanosine, 2-O-ribosylphosphate guanosine, 7-methylguanosine, hydroxyguanosine, 7-aminomethyl-7-deazaguanosine, 7-cyano-7-deazaguanosine, N2,N2-dimethylguanosine, N2,7,2-0-trimethylguanosine, N2,2-0-dimethylguanosine, 1,2-0-dimethylguanosine, 2-0-methylguanosine, N2,N2,2-0-trimethylguanosine, N2,N2J-trimethylguanosine, isoguanosine;4-demethyl wyoside, epoxy braided glycoside, undermodified hydroxy wyoside, methylated undermodified hydroxy wyoside, isowyoside, peroxy wyoside, galactosyl-braided glycoside, mannosyl-braided glycoside, braided glycoside, archaeoside, wyoside, methyl wyoside, wyoside, 7-aminocarboxypropyl demethyl wyoside, 7-aminocarboxypropyl wyoside, 7-aminocarboxypropyl wyoside methyl ester, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio 7-Deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, N1-methyl-guanosine, 2'-amino-3'-deoxyguanosine, 2'-azido-2'-deoxyguanosine, 2'-fluoro-2'-deoxyguanosine;2-thiouridine, 3-(3-amino-3-carboxypropyl)uridine, 3-methyluridine, 4-thiouridine, 5-methyl-2-thiouridine, 5-methylaminomethyluridine, 5-carboxymethyluridine, 5-carboxymethylaminomethyluridine, 5-hydroxyuridine, 5-methyluridine, 5-taurinomethyluridine, 5-carbamoylmethyluridine, 5-(carboxyhydroxymethyl)uridine methyl ester, dihydrouridine, 5-methyldihydrouridine, 5-methylaminomethyl-2-thiouridine, 5-(carboxyhydroxymethyl)uridine, 5-(carboxyhydroxymethyl)-2'-O-methyluridine methyl ester, 5-(Isopentenylaminomethyl)uridine, 5-(Isopentenylaminomethyl)-2-thiouridine, 3,2-O-dimethyluridine, 5-carboxymethylaminomethyl-2-O-methyluridine, 5-carbamoylhydroxymethyluridine, 5-carbamoylmethyl-2-0-methyluridine, 5-carbamoylmethyl-2-thiouridine, 5-methoxycarbonylmethyl-2-O-methyluridine, 5-(Isopentenylaminomethyl)-2-0-methyluridine, 5,2-0-dimethyluridine, 2-O-methyluridine, 2-0-methyl-2-thiouridine, 2-thio-2-0-methyluridine, uridine 5-oxyacetic acid (uridine 5-oxyacetic acid), 5-methoxycarbonylmethyluridine, uridine 5-oxyacetic acid methyl ester, 5-methoxyuridine, 5-aminomethyl-2-thiouridine, 5-carboxymethylaminomethyl-2-thiouridine, 5-methylaminomethyl-2-selenouridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-taurinemethyl-2-thiouridine, pseudouridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine, 1-methylpseudouridine, 3-methylpseudouridine, 2-0-methylpseudouridine, 5-formyluridine, 5-aminomethyl-2-geranyluridine, 5-taurinemethyluridine, 5-iodouridine, 5-bromouridine, 2'-methyl-2'-deoxyuridine, 2'-amino-2'-deoxyuridine, 2'-azido-2'-deoxyuridine and 2'-fluoro-2'-deoxyuridine;Inosine, 1-methylinosine, 1,2-0-dimethylinosine and 2-0-methylinosine, 5-aza-uridine, 2-thio-5-aza-uridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 1-taurinemethyl-pseudouridine, 5-taurinemethyl-2-thio-uridine, 1-taurinemethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio Preferably, uridine, N1-methyl-pseudo-uridine, 2'-fluoro-2'-deoxycytidine, 5-iodocytidine, 5-methylcytidine, 2'-thiouridine, 5-iodouridine and / or 5-methyl-uridine.
[0100] The term "modified nucleotide" includes nucleotides containing isotopes (such as deuterium). The term "isotope" refers to an element with the same number of protons but with different numbers of neutrons and resulting in different mass numbers. Therefore, for example, the isotope of hydrogen is not limited to deuterium, but also includes tritium. In addition, polyribonucleotides can also include isotopes of other elements, which include, for example, carbon, oxygen, nitrogen and phosphorus. Modified nucleotides can also be deuterated or contain other isotopes of hydrogen or oxygen, carbon, nitrogen or phosphorus.
[0101] In the case that the polyribonucleotide according to the present invention is produced by in vitro transcription in the presence of four kinds of nucleotide types, i.e. A, C, G and U nucleotides, the total number of modified nucleotide types can be 0,1,2,3 or 4. In other words, in some embodiments, at least one nucleotide of a kind of nucleotide type, for example at least one U nucleotide, can be a modified nucleotide. In some embodiments, at least one nucleotide in two kinds of nucleotide types in total, for example at least one U nucleotide and at least one C nucleotide can be a modified nucleotide. In some embodiments, at least one nucleotide in three kinds of nucleotide types in total, for example at least one G nucleotide, at least one U nucleotide and at least one C nucleotide can be a modified nucleotide. In some embodiments, at least one nucleotide in all four kinds of nucleotide types can be a modified nucleotide. In all of these embodiments, one or more nucleotides of each nucleotide type may be modified and the percentage of modified nucleotides of each nucleotide type is 0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 100%.
[0102] In some embodiments, the total percentage of the modified nucleotides comprised in the polyribonucleotide according to the present invention is 0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 100%.
[0103] Preferably, the polyribonucleotide according to the present invention is characterized in that 5 to 30% of U nucleotides and 5 to 30% of C nucleotides are modified. The modified U nucleotide is preferably 5-iodouridine, and the modified C nucleotide is preferably 5-iodine.
[0104] More preferably, the polyribonucleotide according to the present invention is characterized in that 7.5 to 25% of U nucleotides and 7.5 to 25% of C nucleotides are modified. The modified U nucleotides are preferably 5-iodouridine, and the modified C nucleotides are preferably 5-iodine.
[0105] The present invention further relates to polyribonucleotides obtainable by any of the above methods.
[0106] As mentioned above, polyribonucleotide according to the present invention comprises 5'UTR, coding sequence, optionally 3'UTR and modified poly (A) tail encoded by the first and second nucleotide sequences.Preferably, polyribonucleotide comprises 5'UTR with at least one RBS and / or IRES, coding sequence with optimized codon, optionally 3'UTR with at least one regulatory sequence and modified poly (A) tail.In addition, polyribonucleotide can be optionally included in other nucleotides except A nucleotides after modified poly (A) tail, preferably a G nucleotide.
[0107] About polyribonucleotide and the method for obtaining said polyribonucleotide, like the nucleotide sequence of the nucleotide sequence of the above binding coding mRNA molecule and the coding modified poly (A) tail, said mRNA molecule and said modified poly (A) tail and the description that generation comprises the method for polyribonucleotide of the sequence of amino acid sequence of the present invention and modified poly (A) tail being applicable.In addition, other features of this polyribonucleotide also can be as mentioned above.
[0108] In some embodiments, polyribonucleotide as above comprises the modified Nucleotide of one or more types.In the case of using the polyribonucleotide transfection cell, this can be favourable for reducing immunogenicity.In addition, for increasing the amount of the aminoacid sequence that can be obtained by the polyribonucleotide in the cell, can be favourable.
[0109] About polyribonucleotide and the method for obtaining said polyribonucleotide, be applicable as the description made by the method for polyribonucleotide of the nucleotide sequence of above binding coding mRNA molecule and coding modified poly (A) tail, said mRNA molecule and said modified poly (A) tail and use modified nucleotide to produce the polyribonucleotide that comprises the sequence of amino acid sequence of coding according to the present invention and modified poly (A) tail.In addition, other features of this polyribonucleotide also can be as mentioned above.
[0110] The present invention further relates to a pharmaceutical composition comprising polyribonucleotides as above together with a pharmaceutically acceptable carrier (carrier).Preferably with an effective amount, i.e., enough to induce a detectable therapeutic response in the object to which the pharmaceutical composition is given, the polyribonucleotides are included.Polyribonucleotides or pharmaceutical compositions of the present invention can be in sterile aqueous or non-aqueous solutions, suspensions and emulsions, as well as ointments and suppositories, but can also have the form of powders, tablets or aerosols.
[0111] As used herein, the term "pharmaceutically acceptable carrier" refers to chemical compounds, materials, ingredients, and / or compositions that are suitable, within the scope of sound medical judgment, for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio. Thus, a pharmaceutically acceptable carrier is an inactive substance formulated with a pharmaceutically active substance to facilitate its processing, with respect to dosage, adsorption, solubility, or pharmacokinetics.
[0112] Examples of suitable pharmaceutically acceptable carriers are well known in the art and include phosphate buffered saline, buffer, water, emulsions (such as oil / water emulsions), various types of wetting agents, and sterile solutions. Specifically, aqueous carriers include water, alcohol / water solutions, emulsions or suspensions, including saline and buffered media. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), and organic esters (such as ethyl oleate). Other examples of pharmaceutically acceptable carriers include, but are not limited to, saline, Ringer's solution and dextrose solution, citrate, phosphate, and other organic acids; salt-forming counterions such as sodium and potassium; low molecular weight (>10 amino acid residues) polypeptides; proteins (e.g., serum albumin) or gelatin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as histidine, glutamine, lysine, asparagine, arginine, or glycine; carbohydrates including glucose, mannose, or dextrin; monosaccharides; disaccharides; other sugars such as sucrose, mannitol, trehalose, or sorbitol; chelates; The invention relates to pharmaceutically acceptable carriers and their preparations. The pharmaceutically acceptable carriers and their preparations are described in more detail in Remington's Pharmaceutical Sciences, 17th ed., 1985, Mack Publishing Co. In addition, preservatives, stabilizers and other additives may be present, such as, for example, octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens, such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol. Suitable pharmaceutically acceptable carriers and their preparations are described in more detail in Remington's Pharmaceutical Sciences, 17th ed., 1985, Mack Publishing Co. In addition, preservatives, stabilizers and other additives may be present, such as, for example, antimicrobial agents, antioxidants, chelating agents, and inert gases, nanosystems or liposomes, etc.
[0113] Pharmaceutical composition of the present invention can be administered by various types of administration forms well known by persons skilled in the art, such as the use of needle injection, inhaler, emulsifiable paste, foam, gel, lotion and ointment.The dosage and the persistent period of effect depend on the function that the polyribonucleotide will realize, and must be adjusted in a targeted manner in each case.The persistent period of effect will be as long as possible, for example, if the polyribonucleotide is used for the chronic treatment of the disease caused by gene defect, and for other indications, then it can be adjusted to specific time window.In addition, the systemic administration of the one or more polyribonucleotides described above is possible.
[0114] About polyribonucleotide, be applicable to the description that the method for the polyribonucleotide of the sequence of poly (A) tail that comprises the nucleotide sequence of the nucleotide sequence of coding mRNA molecule and coding modified poly (A) tail and generation comprises according to the present invention coded amino acid sequence and modified poly (A) tail.In addition, other features of this polyribonucleotide also can be as mentioned above.
[0115] Figure 1 :Based on poly(A) 120 、Poly (A) 3x40_6 and poly(A) 2x60_6 Quantification of the percentage of recombinant clones of the constructs versus poly(A) tail recombination.
[0116] Figure 2 : Quantification of poly(A) tail recombination based on the percentage of recombinant clones using different one nucleotide spacers.
[0117] Figure 3 : Determination of luciferase protein activity and mRNA degradation kinetics of different poly(A) constructs in A549 cells 24 h after transfection (250 ng / well). (a) Luciferase activity in protein lysates from A549 cells transfected with different poly(A) constructs. (b) Quantification of luciferase mRNA in A549 cells. (c) Luciferase luminescence values (RLU; a) were divided by the amount of mRNA (real-time quantitative PCR data; b) and these ratios were normalized to those of the poly(A) constructs. 120 The mRNA productivity was calculated by comparing the ratio observed for each construct. Statistical significance was assessed by two-way ANOVA test, p values: *p<0.5, **p<0.01, ***p<0.001, ****p<0.0001, n=6.
[0118] Figure 4 :By using poly(A) 120 or poly(A) 2x60_6The supernatant of HEK293 cells transfected with the construct was subjected to quantification of secreted human erythropoietin (hEPO) protein levels measured by ELISA 24 hours after transfection (250 ng / well). Values represent the mean ± standard deviation of three replicates. Statistical significance was assessed by two-way ANOVA test, p values: **p<0.01, ***p<0.001, n=3.
[0119] Figure 5 : Determination of luciferase protein activity and mRNA quantification of different poly(A) tail constructs in A549 cells 24 hours after transfection (250 ng / well). (a) Luciferase activity in protein lysates from A549 cells transfected with different poly(A) tail constructs. (b) Luciferase mRNA quantification in A549 cells transfected with different poly(A) tail constructs. (c) Luciferase luminescence values (RLU; a) were divided by the amount of mRNA (real-time quantitative PCR data; b) and these ratios were normalized to the amount of mRNA transfected with poly(A) tail constructs. 120 Luciferase mRNA productivity was calculated by comparing the ratio observed for the constructs. Statistical significance was assessed by two-way ANOVA test, p values: *p<0.5, ****p<0.0001, n=6.
[0120] Other aspects and advantages of the present invention will be described in the following examples, which are given for illustrative rather than limiting purposes.Every publication, patent, patent application or other document cited in this application is incorporated herein by reference in its entirety. Example
[0121] Methods and materials for use in the present disclosure are described herein; other suitable methods and materials known in the art may also be used. These materials, methods, and examples are illustrative only and are not intended to be limiting.
[0122] Table 2 lists the abbreviations used in this article and their corresponding descriptions.
[0123] Table 2
[0124]
[0125]
[0126] Materials and Methods
[0127] Materials, equipment, software, and test systems used.
[0128] The materials are listed in Table 3.
[0129] Table 3
[0130]
[0131]
[0132] The equipment is listed in Table 4.
[0133] Table 4
[0134]
[0135]
[0136] The software is listed in Table 5.
[0137] Table 5
[0138]
[0139] The test systems are listed in Table 6.
[0140] Table 6
[0141]
[0142] Plasmid preparation
[0143] Synthetic poly(A) tail sequences were introduced into the pUC57-kanamycin vector backbone as annealed complementary oligonucleotides or as fragments generated by PCR-based strategies. 2x60_6 Constructs and poly(A) 3x40_6 The sequence of the construct is designed with a specific set of complementary oligonucleotides and annealed. Poly(A) is generated by PCR 120 、Poly (A) 2x60_c 、Poly (A) 2x60_G , and poly(A) 2x60_T Synthetic poly(A) constructs.
[0144] The annealing method of two sets of complementary oligonucleotides was as follows: 100 μM of each oligonucleotide was mixed with 40 μl of annealing buffer and incubated at 95°C (10 mM Tris HCl, 50 mM NaCl, 1 mM EDTA, pH 7.5) for 5 minutes. After the reaction, the mixture was cooled to room temperature before restriction digestion (BgIII-BstBI).
[0145] For high performance of the PCR reaction, Phusion High Fidelity PCR Master Mix was used. In addition to the master mix containing 2x Phusion DNA polymerase, nucleotides and optimized reaction buffer (including MgCl2), 0.5 μM forward and reverse primers, 3% DMSO and 100 ng template DNA were added to the reaction. Each reaction total volume of 25 μl was first denatured at 98°C for 30 seconds, followed by 30 cycles of 10 seconds at 98°C, annealing at 72°C for 30 seconds, and extension at 72°C for 30 seconds / kb. The final extension was performed at 72°C for 10 minutes. The size of the PCR product was confirmed on a 1% agarose gel, and the desired band was purified using the NecleoSpin gel and PCR purification kit. The purified PCR product was digested with Nhel-BstBI and stored at -20°C until further use.
[0146] After restriction enzyme digestion of the annealed oligonucleotides (Bglll-BstBI) and the PCR fragment (Nhel-BstBI), the poly(A) tail construct was cloned into the correspondingly digested pUC57-kanamycin vector containing the coding region of choice (firefly luciferase, hEPO, d2EGFP).
[0147] The segment poly(A) sequences and corresponding cloning strategies using PCR primer sets or oligonucleotides are shown in Table 7.
[0148] Table 7
[0149]
[0150] Cloning into E. coli
[0151] The conjugate was purified using chloroform-ethanol precipitation and electroporated into the Escherichia coli DH10B strain. For electroporation, a Gene Pulser II from Biorad was used. The electroporation conditions followed were: 25pF, 200 ohms, 1.8kV. After electroporation, the bacteria were grown in 2mL of LB medium at 30°C for 1.5 hours. Afterwards, the culture was centrifuged at 5000rpm for 10 minutes at room temperature. The supernatant was discarded, and the precipitation was resuspended in 200 μL of fresh LB medium. Afterwards, 100 μL were placed in an LB-agar plate containing appropriate antibiotics (a final concentration of 50 μg / mL of kanamycin or a final concentration of 100 μg / mL of ampicillin). The plate was incubated overnight at 30°C.
[0152] Plasmid preparation using Mini-prep kit
[0153] The clones were inoculated in LB medium containing appropriate antibiotics (final concentration of 50 μg / mL kanamycin or final concentration of 100 μg / mL ampicillin), and grown overnight at 30°C in a bacterial shaker (250 rpm). Afterwards, the plasmid was isolated from the overnight culture using the Mini-Prep kit. The insertion of the plasmid was tested using restriction enzyme digestion and confirmed by sequencing. For correct clones, glycerol stock was prepared by adding 200 μL of autoclaved glycerol to 800 μL of overnight bacterial culture. The glycerol stock was stored at -80°C.
[0154] Plasmid preparation using the Maxi-Prep kit
[0155] Use Maxi-Prep test kit to prepare the plasmid for producing RNA.The glycerol stock from required clone (one or more) is inoculated into 5mL of LB culture medium containing suitable antibiotic (final concentration is 50 μ g / mL kanamycin or final concentration is 100 μ g / mL ampicillin), and the culture is grown overnight at 30 ℃ in a bacterial shaking table (250rpm).Inoculate 300mL of LB culture medium containing suitable antibiotic (final concentration is 50 μ g / mL kanamycin or final concentration is 100 μ g / mL ampicillin) with 3mL in this starting culture, spend the night at 30 ℃ in a bacterial shaking table (250rpm).At 4 ℃, with 5000rpm, overnight culture was centrifuged for 30 minutes.Discard supernatant, and bacterial precipitation is used to separate plasmid.
[0156] mRNA production
[0157] To generate in vitro transcribed mRNA, the plasmid was linearized by BstBI digestion and purified by chloroform extraction and ethanol precipitation. The purified linear plasmid was used as a template for in vitro transcription. The plasmid template (0.5 μg / μL) was subjected to in vitro transcription using 3U / μl T7 RNA polymerase, transcription buffer II, 1U / μl RiboLock RNase inhibitor, 0.015U / μl inorganic pyrophosphatase 1 and the defined selected ribonucleotides. The complete IVT mixture was incubated at 37°C for 2 hours. Afterwards, 0.01U / μl DNase I was added and incubated at 37°C for another 45 minutes to remove the plasmid template. The RNA was precipitated with ammonium acetate at a final concentration of 2.5mM, followed by two washing steps with 70% ethanol. The precipitate was resuspended in water for injection. The C1-m7G cap structure was enzymatically added to the 5' end of the previously denatured transcript (1 mg / ml) by 0.5 mM vaccinia virus capping enzyme at 80°C for 5 minutes. The capping reaction mixture also contained 1x capping buffer, 0.5 mM GTP, 0.2 mM S-methyladenosine, 2.5 U / μl mRNA cap 2'-o-methyltransferase and 1 U / μl RiboLock RNase inhibitor. The capping mixture was incubated at 37°C for 60 minutes, and then the RNA was precipitated with ammonium acetate at a final concentration of 2.5 mM, and two washing steps were performed with 70% ethanol. The precipitate was resuspended in water for injection.
[0158] RNA quality and concentration were measured spectrophotometrically on a NanoDrop 2000C, and its correct size and purity were determined by automated capillary electrophoresis.
[0159] Cell culture
[0160] A549 (ACC-107) and HEK293 (ACC-305) cells were purchased from DSMZ. All cells were cultured in minimal essential medium (MEM) containing glutamine. The medium was supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin / streptomycin. The cells were cultured at 37°C in a humidified 5% CO2 incubator.
[0161] In vitro transfection
[0162] Two cell lines, A549 and HEK293, were transfected with 250 ng of mRNA per well. For the purpose of firefly luciferase and hEPO ELISA assays, A549 and HEK293 cells were cultured at 2x10 4 cells / well and 4x10 4 Cells were seeded at a density of 10 cells / well in a 96-well plate. 24 hours after seeding, the cells were transfected using a commercial transfection reagent. 2000 cells were transfected. 2 μl The complexes were prepared at a ratio of 2000 / 1 μg mRNA.
[0163] Dilute mRNA 1:20 in water and separately 1:10 in serum-free MEM. 2000. Adding mRNA to 2000, and then incubated at room temperature for 20 minutes. The final mRNA / The concentration of the 2000 solution was 25 ng / μl and serial dilutions were performed 1:2. 10 μl of the complex solution was added to the cells and the cells were incubated for 24 and 48 hours, respectively. For each mRNA construct, three or six replicates were prepared.
[0164] Flow cytometric analysis of d2EGFP
[0165] Cells were washed with PBS, separated with TrypLE, and resuspended in flow cytometry buffer (PBS supplemented with 10% FBS). Shortly before measurement, cells were stained with propidium iodide to distinguish live cells from dead cells (1 μg / mL). Live cells (>97%) were further gated to distinguish cells expressing d2EGFP from cells that did not express it. Analysis was performed on an Attune acoustic focusing cytometer with Attune cell counting software (version 2.1) and FlowJo (version 10).
[0166] Firefly luciferase assay
[0167] To detect firefly luciferase activity, the assay was performed 24 hours after transfection. At appropriate time points, the cells were washed with PBS and then 100 μl of lysis buffer (25 mM Tris-HCl, 0.1% TritonX-100, pH 7.4) was added. The cells were shaken at room temperature for 20 minutes. After lysis, luciferase activity was measured using InfiniteR 200PRO with 50 μl of cell lysate by photon luminescence emission for 5s. Bovine serum albumin was used as a standard and the amount of protein in each sample was quantified in 5 μl of cell lysate by BioRad protein assay. Luciferase values were standardized to protein concentrations.
[0168] RNA isolation and reverse transcription
[0169] To determine the actual amount of mRNA 24 hours after transfection, cultured cells (A549, HEK293) were lysed and RNA was isolated using a single-shot cell lysis kit according to the manufacturer's protocol. cDNA was synthesized from the lysate (1 μg RNA) using the iScript Select cDNA Synthesis Kit and oligo (dT) primers according to the manufacturer's instructions. The synthesized cDNA was stored at -20°C.
[0170] Quantitative real-time polymerase chain reaction (qPCR)
[0171] Real-time quantitative PCR was performed on a Roche Light Cycler 96 using short hydrolysis probes for d2EGFP and luciferase targets (universal probe libraries #37 and #29). For d2EGFP, the following primers were used: 5'-cctgaagttcatctgcacca-3' and 5'-ctcgtgaccaccctgacc-3'; and for the luciferase target, the following primers were used: 5'-acgccgagtacttcgagatg-3' and 5'-attcagcccatagcgcttc-3'. Absolute mRNA values were calculated by interpolation from the standard curve.
[0172] Statistical analysis
[0173] Each experiment was performed with at least three technical replicates for each sample. Unless otherwise stated, the results are shown as mean ± SD. Statistical analysis was performed using GraphPad Prism software (version 6). The D'Agostino-Pearson overall normality test was used to test the normal distribution of the data. Multiple comparisons were performed by two-way ANOVA followed by Sidak test (paired comparisons) or Dunett test (many-to-one comparisons). p values ≤ 0.05 were considered statistically significant.
[0174] Segmental poly(A) tails can greatly reduce bacterial recombination
[0175] It was examined whether the use of segmented poly(A) tails would affect plasmid recombination after transformation into E. coli. To test this, open reading frame sequences of different genes (luciferase, d2EGFP, hEPO) were combined with three poly(A) constructs: poly(A) 120 , Poly(A)2 x60_6 and poly(A) 3x40_6Any combination of and cloned into pUC57-kanamycin vector. After transformation into E. coli, clones were screened for insertion and positive clones containing the desired insert were additionally screened for the length of the corresponding poly(A) tail. For each of the three poly(A) tail constructs, the poly(A) tail was digested with a restriction enzyme and the digests were resolved on a fragment analyzer (capillary gel electrophoresis) to measure the size of the corresponding poly(A) tail. It was observed that the poly(A) tail containing the homologous poly(A) tail 120 Recombination of the poly(A)-tail occurred in more than 50% of the clones. 3x40_6 or poly(A) 2x60_6 , using poly(A) 2x60_6 Most stable clones obtained from plasmids with significantly reduced recombination in E. coli (<20% recombination) ( Figure 1 ; Table 8). This trend was observed in all three open reading frame sequences tested, indicating that the reduction in recombination was sequence independent. 2x60_6 The most favorable effect of the structure - the reorganization is 20% or less.
[0176] Table 8
[0177]
[0178] Effect of one nucleotide long spacer in poly(A) tail on recombination
[0179] By studying the open reading frame sequence of firefly luciferase and the corresponding poly(A) 2x60_c 、Poly (A) 2x60_G or poly(A) 2x60_T Cloning of constructs was checked for poly(A) 2x60 Effect of one nucleotide long spacer in constructs (C, T or G) on recombination in E. coli. Interestingly, constructs containing G as spacer in the poly(A) tail did not recombine at all. Spacers with a single T recombined in 10% of cases, while spacers with C as spacer nucleotide recombined in 50% of cases ( Figure 2 ), which at first glance seems similar to the A120( Figure 1 ) observed a similar recombination efficiency, but still significantly lower. This is evident from Table 9 below, which summarizes the Figure 1 and 2 Recombination efficiencies observed for the constructs tested in .
[0180] Table 9
[0181] Poly(A) <![CDATA[ picture ]]> <![CDATA[ n ]]> <![CDATA[ Recombination rate ]]> <![CDATA[Poly(A) 2x60_6 > <![CDATA[ 1 ]]> <![CDATA[ 81 ]]> <![CDATA[ 19% ]]> <![CDATA[Poly(A) 3x40_6 > <![CDATA[ 1 ]]> <![CDATA[ 20 ]]> <![CDATA[ 35% ]]> <![CDATA[Poly(A)]]> 120 > <![CDATA[ 1 ]]> <![CDATA[ 37 ]]> <![CDATA[ 54% ]]> <![CDATA[Poly(A) 2x60_G > <![CDATA[ 2 ]]> <![CDATA[ 16 ]]> <![CDATA[ 0% ]]> <![CDATA[Poly(A)]]> 2x60_T > <![CDATA[ 2 ]]> <![CDATA[ 10 ]]> <![CDATA[ 10% ]]> <![CDATA[Poly(A)]]> 2x60_C > <![CDATA[ 2 ]]> <![CDATA[ 10 ]]> <![CDATA[ 50% ]]>
[0182] Effects of a six-nucleotide-long spacer on mRNA and protein levels
[0183] In the use of poly (A) 2x60_6 、Poly (A) 3x40_6 or poly(A) 120 Luciferase protein and mRNA degradation were studied in A549 cells 24 hours after transfection of constructs with luciferase mRNA. 120 Compared to the baseline, using segment poly(A) 2x60_6 The construct significantly increased the protein level after transfection ( Figure 3 ). For different poly(A) forms containing modified luciferase mRNA across, no significant differences were observed between the amounts of mRNA.
[0184] In addition, using human erythropoietin (hEPO) as a prototype for secreted proteins and a short mRNA (0.9 kb), the effects of poly(A) segmentation on transcription and translation of physiological targets were tested. The codon-optimized sequence encoding hEPO was cloned into the pUC57-kanamycin vector at the poly(A) 120 or poly(A) 2x60_6 24 hours after transfection, hEPO protein concentration was determined by ELISA ( Figure 4 Significant differences were observed between the two poly(A) tail constructs compared, with the poly(A) 2x60_6 The construct is higher than the standard poly(A) 120 The construct produced significantly more protein.
[0185] Effects of a one-nucleotide-long spacer on mRNA and protein levels
[0186] Poly(A) was tested 2x60 -Effects of a single spacer nucleotide within the tail on protein expression and mRNA productivity. Luciferase mRNA expression and protein activity were determined by using the corresponding poly(A) 2x60 The assay was performed by transfecting A549 cells with mRNA constructs containing a single C, T, or G spacer nucleotide in the -tail. As a benchmark, a standard poly(A) 120 There were no significant differences in protein expression between all three single nucleotide spacer constructs, but there was a significant difference in protein expression with poly(A) 120 All of them produced significantly more protein than the constructs ( Figure 5 ). The mRNA productivity was calculated and the construct with C as the spacer appeared to have the highest productivity overall. 2x60_c 、Poly (A)2x60_G 、Poly (A) 2x60_T Compared with any of the 120 The mRNA productivity of the Sequence Listing <110> Azeris <120> Plasmid containing a sequence encoding mRNA with a segmented poly(A) tail <130> AB2096 PCT S3 <150> EP 18 19 9857.6 <151> 2018-10-11 <160> 9 <170> BiSSAP 1.3.6 <210> 1 <211> 34 <212> DNA <213> Artificial sequence <220> <223> PCR Primer Forward / Oligo I <400> 1 gtgactgcta gctaatacga ctcactatag ggag 34 <210> 2 <211> 163 <212> DNA <213> Artificial sequence <220> <223> PCR Primer Reverse / Oligo II <400> 2 agtcacttcg aatttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 120 tttttttttt ttagatcttt acacggcgat cttgccgccc ttc 163 <210> 3 <211> 150 <212> DNA <213> Artificial sequence <220> <223> PCR Primer Forward / Oligo I <400> 3 gtgactagat ctaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60 aaaaaaaaaa aaatgcataa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 120 aaaaaaaaaa aaaaaaaatt cgaagtgact 150 <210> 4 <211> 150 <212> DNA <213> Artificial sequence <220> <223> PCR Primer Reverse / Oligo II <400> 4 agtcacttcg aatttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60 tttttttttt ttatgcattt tttttttttt tttttttttt tttttttttt tttttttttt 120 ttttttttttttttttttag atctagtcac 150 <210> 5 <211> 156 <212> DNA <213> Artificial sequence <220> <223> PCR Primer Forward / Oligo I <400> 5 gtgactagat ctaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaatgcataa 60 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaga tatcaaaaaa aaaaaaaaaa 120 aaaaaaaaaa aaaaaaaaaa aaaattcgaa gtgact 156 <210> 6 <211> 156 <212> DNA <213> Artificial sequence <220> <223> PCR Primer Reverse / Oligo II <400> 6 agtcacttcg aatttttttt tttttttttt tttttttttt tttttttttt ttgatatctt 60 tttttttttt tttttttttt tttttttttt tttttttttat gcattttttt tttttttttt 120 tttttttttt tttttttttt ttttagatct agtcac 156 <210> 7 <211> 164 <212> DNA <213> Artificial sequence <220> <223> PCR Primer Reverse / Oligo II <400> 7 agtcacttcg aatttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60 tttttttttt ttgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt 120 tttttttttt tttagatctt tacacggcga tcttgccgcc cttc 164 <210> 8 <211> 164 <212> DNA <213> Artificial sequence <220> <223> PCR Primer Reverse / Oligo II <400> 8 agtcacttcg aatttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60 tttttttttt ttcttttttt tttttttttt tttttttttt tttttttttt tttttttttt 120 tttttttttt tttagatctt tacacggcga tcttgccgcc cttc 164 <210> 9 <211> 164 <212> DNA <213> Artificial sequence <220> <223> PCR primer reverse / Oligomer II <400> 9 agtcacttcg aatttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60 tttttttttt ttattttttt tttttttttt tttttttttt tttttttttt tttttttttt 120 tttttttttt tttagatctt tacacggcga tcttgccgcc cttc 164
Claims
1. A DNA plasmid comprising DNA, wherein the sequence of the DNA comprises: (i) a first nucleotide sequence encoding an mRNA molecule, and a (ii) a second nucleotide sequence encoding a modified poly(A) tail, The second nucleotide sequence is characterized in that it consists of: (a) at least two A elements, each of which is defined as a nucleotide sequence consisting of 55 to 65 T nucleotides, and (b) at least one S element, each of which consists of: (b1) a nucleotide that is not a T or G nucleotide, or (b2) 5 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide; where the total number of A elements is one more than the total number of S elements, and Any two A elements are separated by an S element.
2. The DNA plasmid of claim 1, wherein any one of the S elements consists of one C nucleotide or one A nucleotide.
3. The DNA plasmid of claim 1, wherein any one of the S elements consists of one C nucleotide.
4. The DNA plasmid of claim 1 or 2, wherein the number of A elements is two, three or four.
5. The DNA plasmid of claim 1 or 2, wherein the number of A elements is four, and wherein the nucleotide sequences of the four A elements together have a total length of 240 nucleotides.
6. The DNA plasmid of claim 4, wherein the number of A elements is four, and wherein the nucleotide sequences of four of the A elements together have a total length of 240 nucleotides.
7. The DNA plasmid of claim 5, wherein each A element has a length of 60 nucleotides.
8. The DNA plasmid of claim 1 or 2, wherein the number of A elements is two, and wherein the nucleotide sequences of two of the A elements together have a total length of 120 nucleotides.
9. The DNA plasmid of claim 4, wherein the number of A elements is two, and wherein the nucleotide sequences of two of the A elements together have a total length of 120 nucleotides.
10. The DNA plasmid of claim 8, wherein each A element has a length of 60 nucleotides.
11. A bacterial host cell comprising the DNA plasmid according to any one of claims 1 to 10.
12. The bacterial host cell of claim 11, which is an Escherichia coli cell.
13. The bacterial host cell of claim 11, which is Escherichia coli recA - cell.
14. Use of a nucleotide sequence encoding a modified poly(A) tail as defined in claim 1(ii) or any one of claims 2 to 10 in the preparation of a DNA plasmid showing reduced recombination during amplification in a bacterial host cell, wherein the nucleotide sequence is located downstream of a nucleotide sequence encoding an mRNA molecule.
15. Use of a nucleotide sequence encoding a modified poly(A) tail as defined in claim 1(ii) or any one of claims 2 to 10 to reduce recombination during amplification of a DNA plasmid in a bacterial host cell.
16. A method for reducing recombination of a DNA plasmid comprising a DNA sequence encoding an mRNA molecule and a poly(A) tail located downstream thereof during amplification in a bacterial host cell, wherein the reduction is achieved by replacing the portion of the DNA sequence encoding the poly(A) tail by a nucleotide sequence encoding a modified poly(A) tail as defined in claim 1(ii) or any one of claims 2 to 10.
17. a method for producing polyribonucleotide, said polyribonucleotide comprises an amino acid encoding sequence and a sequence of a modified poly (A) tail encoded by a nucleotide sequence as defined in claim 1 (ii) or in any one of claim 2 to 10, said method comprising the step of producing said polyribonucleotide by in vitro transcription from the DNA plasmid described in any one in claim 1 to 10.
18. The method of claim 17, wherein the polyribonucleotide is produced by carrying out in vitro transcription in the presence of unmodified and / or modified Nucleotide.
19. A polyribonucleotide obtainable by the method of claim 17 or 18.
20. the described polyribonucleotide of claim 19, wherein said polyribonucleotide comprises the modified nucleotide of one or more types.
21. A pharmaceutical composition comprising the polyribonucleotide described in any one of claims 19 to 20 together with a pharmaceutically acceptable carrier.
